Pfizer Licenses Potelligent CHOK1SV Cell Line

August 6, 2013
BioPharm International Editors

The licensed cell line combines BioWa's engineered glycosylation Potelligent Technology with Lonza's GS Gene Expression System.

BioWa, Inc. and Lonza have entered intoresearch agreements with Pfizer allowing the use of the Potelligent CHOK1SV Cell Line in the research and development of multiple proprietary antibodies in Pfizer’s pipeline.

Potelligent CHOK1SV is a host cell line for manufacturing recombinant antibodies that combines BioWa’s engineered glycosylation Potelligent Technology with  Lonza’s GS Gene Expression System. The GS System includes Lonza’s host cell line, CHOK1SV.

The Potelligent CHOK1SV Cell Line retains the desirable features of a high-producing cell line (robust, high-yielding, scalable), with the advantage of a proven bioprocess platform for the CHOK1SV Cell Line, the company reports. Antibodies produced by this cellline exhibit enhanced antibody dependent cellular cytotoxicity (ADCC) and can exert potent cytotoxic effects even when their target antigen is low. In addition, they work in whole blood and retain all other desirable features of common antibodies.

Source: BioWa Inc.

Related Content:

News | Industry News | Biopharma News